Table 2 Differences of variables between the two WMLs groups
Variable | moderate to severe WMLs group | mild WMLs group | Test Value | P Value |
|---|---|---|---|---|
(n = 63) | (n = 188) | |||
Age, y, median (IQR) | 77 (74,79) | 71 (66,75) | 6.241 | < 0.001 |
Male, n (%) | 36 (57.1) | 102 (54.3) | 0.159 | 0.690 |
Smoking, n (%) | 14 (22.2) | 48 (25.5) | 0.278 | 0.598 |
Hypertension, n (%) | 60 (95.2) | 136 (72.3) | 14.459 | < 0.001 |
Diabetes mellitus, n (%) | 17 (27.0) | 35 (18.6) | 2.011 | 0.156 |
Hyperlipidemia, n (%) | 12 (19.0) | 31 (16.5) | 0.218 | 0.641 |
Congestive heart failure, n (%) | 23 (36.5) | 29 (15.4) | 12.769 | < 0.001 |
Baseline SBP (mm Hg, ‾x ± s) | 152.5 ± 21.0 | 143.7 ± 21.3 | 2.870 | 0.005 |
Baseline DBP (mm Hg, ‾x ± s) | 88.4 ± 14.0 | 85.4 ± 12.9 | 1.490 | 0.139 |
Baseline NIHSS score, median (IQR) | 11 (6,16) | 6 (2,13) | 3.514 | < 0.001 |
Fazekas score, median (IQR) | 3 (3,4) | 2 (1,2) | 12.492 | < 0.001 |
sICH, n (%) | 10 (15.9) | 17 (9.0) | 2.293 | 0.130 |
nsICH, n (%) | 17 (27.0) | 29 (15.4) | 4.212 | 0.040 |
SAP,n (%) | 30 (47.6) | 49 (26.1) | 10.165 | 0.001 |
Anticoagulant therapy, n (%) | 32 (50.8) | 110 (58.5) | 1.144 | 0.285 |
Stroke recurrence, n (%) | 3 (4.8) | 5 (2.7) | 0.166 | 0.411 |
Laboratory findings, mmol/l | ||||
Total cholesterol (‾x ± s) | 4.1 ± 0.8 | 4.1 ± 0.9 | 0.146 | 0.884 |
Triglyceride (‾x ± s) | 1.1 ± 0.5 | 1.2 ± 0.9 | -1.234 | 0.219 |
LDL-C (‾x ± s) | 2.3 ± 0.7 | 2.2 ± 0.7 | 1.232 | 0.221 |
Fasting glucose (‾x ± s) | 6.3 ± 2.4 | 6.2 ± 2.2 | 0.314 | 0.754 |